Daraxonrasib Pill Shows Promise in Pancreatic Cancer Trial
A daily pill combined with chemotherapy left no detectable tumors in five of 61 patients with advanced pancreatic cancer. The early trial had no chemotherapy-only comparison group, and researchers say it is too soon to know whether the cancer will return in those patients.

Five of 61 patients with advanced pancreatic cancer had no detectable tumors after taking daraxonrasib, a daily pill, alongside chemotherapy. The early trial suggests a potential breakthrough in pancreatic cancer treatment, though it is too soon to tell whether the cancer will return in those patients.
Doctors call the disappearance of all detectable tumors a complete response. The trial had no group receiving chemotherapy alone, so it could not directly measure the benefit of adding the pill.
Dr. Wungki Park, an oncologist at Memorial Sloan Kettering Cancer Centre in New York, presented the findings at a cancer therapeutics symposium in Barcelona. He said he had never seen so many tumors disappear in patients whose cancer had spread.
“This is the closest to cure,” Park said.
Most patients saw disease controlled
Tumors shrank or disappeared in 60.7% of patients, while the treatment kept the disease in check in 90.2%. Researchers followed patients for a median of 18 months.
One year after treatment began, 76.6% of patients were alive. Typically, about 40% to 45% of patients given chemotherapy alone survive for a year.
Half the patients lived at least 12.8 months without their cancer getting worse. An international phase three trial is now recruiting.
Among people whose pancreatic cancer has spread to other organs, only about 3% survive for five years. Half of all people diagnosed with pancreatic cancer die within three months.
Earlier trial measured survival
An earlier trial involved about 500 patients whose pancreatic cancer had spread and who had already received standard treatment. Median survival was 13.2 months for those given daraxonrasib, compared with 6.7 months for those on chemotherapy.
The pill targets KRAS, a protein that can send signals telling cancer cells to keep growing. More than nine in 10 pancreatic tumors carry a mutation in the gene that makes the protein.
Daraxonrasib binds to KRAS and blocks those signals. The latest trial tested the pill and chemotherapy together.
Michelle Mitchell, chief executive of Cancer Research UK, said more trials were needed before the treatment could be assessed for use by the UK's National Health Service. Researchers also needed to establish how best to combine it with other therapies.
Dr. Madina Kara, head of research at Pancreatic Cancer UK, urged ministers to increase investment so more patients could join trials. She also called for proven drugs to reach patients across the UK quickly.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Lifestyle · Food & HealthNormal Blood Pressure Chart by Age: Healthy Ranges Explained
Lifestyle · Food & HealthWhat Is Raynaud’s Syndrome? Why Fingers Turn White in the Cold
Lifestyle · Food & Health4 Ways Walking After Meals Helps Your Body, Doctors Say
Lifestyle · Food & Health4 Reasons to Eat Oatmeal, According to Nutrition Experts



















